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Background: Peutz-Jeghers syndrome (PJS) is a rare hereditary syndrome characterized by the occurrence of
hamartomatous polyps in the gastrointestinal tract, mucocutaneous pigmentation and increased risk of cancer in
multiple internal organs. Depending on the studied population, its incidence has been estimated to range from
1:200 000 even up to 1:50 000 births. Being an autosomal disease, PJS is caused in most cases by mutations in the
STK11 gene.
Methods: The majority of causative DNA changes identified in patients with PJS are small mutations and, therefore,
developing a method of their detection is a key aspect in the advancement of genetic diagnostics of PJS patients.
We designed 13 pairs of primers, which amplify at the same temperature and enable examination of all coding
exons of the STK11 gene by the HRM analysis.
Results: In our group of 41 families with PJS small mutations of the STK11 gene were detected in 22 families (54%).
In the remaining cases all of the coding exons were sequenced. However, this has not allowed to detect any
additional mutations.
Conclusions: The developed methodology is a rapid and cost-effective screening tool for small mutations in PJS
patients and makes it possible to detect all the STK11 gene sequence changes occurring in this group.Background
Peutz-Jeghers syndrome (PJS, MIM # 175200) is a rare,
hereditary predisposition characterized by the presence
of hamartomatous polyps in the gastrointestinal tract,
occurrence of lentigines on mucous membranes (mainly
on lips, oral cavity and nostrils) as well as by an in-
creased risk of malignant tumours of various internal or-
gans [1-5]. Depending on the population examined, the
incidence of the syndrome is estimated to fluctuate from
1:200 000 even up to 1:50 000 of births [2].* Correspondence: andp@man.poznan.pl
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reproduction in any medium, provided the orPJS is an autosomal dominant disease caused by muta-
tions in the STK11 gene (MIM # 602216) located on the
small arm of chromosome 19 at position 19p13.3. This
gene comprising 22 637 base pairs consists of 10 exons,
nine of which contain a coding sequence of 48.6 kDa
protein made up of 433 amino acids, which fulfils the
function of serine-threonine kinase. The STK11 is a
suppressor gene, and the kinase encoded by it, plays an
important role in cell metabolism regulation, prolifera-
tion and apoptosis [6,7].
Until recently, over 230 different STK11 gene muta-
tions causing the Peutz-Jeghers Syndrome have been
described in the Human Gene Mutation Database
(HGMD) (http://www.hgmd.cf.ac.uk; the state on 08.
2012). Most of them are small mutations including: 72td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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splicing sites as well as 102 small insertions, deletions
and indel type mutations. The remaining 31 mutations
described concern rearrangements of larger fragments of
the STK11 sequence including 25 large deletions, 3 large
insertions and 3 combined mutations.
In molecular studies of the STK11 gene in patients
with the PJS, mutations are identified in almost all cases
of persons with a positive family history and in approxi-
mately 50-90% when only patients who met the clinical
criteria for PJS were considered [8,9]. Differences in per-
centage proportions of the identified mutations for indi-
vidual patient groups in investigations carried out in
different parts of the world can be attributed both to the
specificity of the population and the way of patient se-
lection for examinations as well as the applied method
of research. Recent studies revealed that copy number
variations (CNV) can be the cause of a considerable pro-
portion, even up to 30%, of PJS cases; this can explain
the lower percentage of mutations detected in patient
groups not tested with methods able to identify large
rearrangements (e.g. MLPA or qPCR) [8,10-12]. How-
ever, small mutations still constitute the highest percent-
age of changes causing the disease and, therefore, the
designing of a rapid and cost-effective method of their
detection is a key aspect in the advancement of genetic
diagnostics of PJS patients.
One of the more novel techniques employed in screen-
ing investigations, which allows identification of small se-
quence changes within the examined fragments is the
high resolution melting (HRM) analysis. The mode of ac-
tion of the method is based on monitoring the behaviour
of DNA fragments, amplified earlier during the denatur-
ation process. The analysis is possible due to the presence
in the reaction mixture of a fluorescent dye which interca-
lates only the double-stranded DNA sending a strong
fluorescent signal allowing to observe the melting process,
i.e. conversion of dsDNA into ssDNA in the course of de-
naturation. Comparison of melting profiles of individual
fragments with one another makes it possible to select
those that indicate differences in the course of denatur-
ation, which at the same time reflect changes in the
sequence. HRM is a screening technique and fails to pro-
vide accurate information about changes in the sequence
and, therefore, all atypical melting profiles require con-
firmation by sequencing. Nevertheless, high sensitivity of
the method, which according to some researchers reaches
even 100%, allows considerable reduction of sequencing
numbers and, consequently, of the cost of analyses, at the
same time maintaining and sometimes even increasing the
identification effectiveness of mutations in comparison
with earlier screening methods [13,14].
The objective of our investigations was to develop a
rapid and effective detection methodology of smallmutations in patients suffering from PJS. Bearing in
mind the heterogenous nature of mutations in the
STK11 gene, the size of gene exons and effectiveness of
individual screening techniques, we decided to develop a
methodology based on the HRM technique.
Methods
The material for investigations was the DNA obtained
from 41 probands with diagnosed Peutz-Jeghers syn-
drome. All patients included in this study fulfilled the
diagnostic criteria of PJS (histopathologically confirmed
hamartomatous polyps and mucocutaneous pigmenta-
tion). The DNA was isolated from peripheral blood and
for this purpose the method of extraction with phenol and
chloroform was used, which was followed by purification
by means of the method of precipitation with ethanol.
In accordance with the standards adopted for HRM,
primers were designed using the Primer3plus (www.
bioinformatics.nl/primer3plus/) software [15]. Each of
the designed primer pairs was checked with respect to
the melting profile. In addition, PCR product heteroge-
neity on agarose gel (1.5% agarose gel, electrophoresis –
30 min., voltage – 100 V) was also checked. On the basis
of these analyses, 13 primer pairs were selected which
allowed examination of all STK11 gene exons together
with sequences of the exon-intron junctions. The
obtained PCR amplicons were contained within the
length range of 150–250 bp, while primers annealing
temperature was 60°C for all pairs. Primers sequences
are collated in Table 1. Fragments were amplified using
Type-it HRM kit [Qiagen] and the analysis was
performed on a Rotor-Gene Q equipment [Qiagen]. The
PCR was performed according to the manufacturer’s in-
structions. PCR conditions were: 95°C for 5 minutes,
followed by 40 cycles of pre-incubation at 95°C for
10 seconds, annealing for 30 seconds at 60°C and exten-
sion at 72°C for 10 seconds. The HRM step was
performed from 60°C to 95°C raising the temperature by
0.1°C degree at each step. The obtained plots were ana-
lyzed using Rotor-Gene Software: 2.0.2.
All samples were analyzed in two separate runs in the
presence of at least three wild type controls sequenced
earlier. Amplicons exhibiting a melting profile different
from wild type controls in the course of HRM were se-
lected and subjected to sequencing. In cases in which no
evident pathogenic mutations were detected during
HRM analyses, sequencing of the entire STK11 gene
coding sequence was performed. The PCR products
were purified by precipitations and sequenced on
both strands using the Big Dye Terminator Cycle Se-
quencing Kit v3.1 Kit (Applied Biosystems). The se-
quence products were purified and separated on an
automated sequencer (ABI 3130xl Genetic Analyzer,
Applied Biosystems).
Table 1 List of primers utilised in the HRM analysis
Amplicon Forward primer Reverse primer Product length [bp] Annealing temperature [°C]
1a GGAAGTCGGAACACAAGGAA CATCAGGTACTTGCCGATGA 231 60
1b CTCCACCGAGGTCATCTACC CCCCAGCAAGCCATACTTAC 221 60
2 AGGCCATCATCCTGACGTT CCCAACACCGGAAAGGATA 159 60
3 CTCCCTGGGCCTGTGAGT CCCTGCCCCGCGCACGCA 165 60
4a CAGGACGGGTGTGTGCTG CCCTAGCACGTGCCTACCT 175 60
4b GCCTGGAGTACCTGCATAGC GTGCAGCCCTCAGGGAGT 172 60
5a CACTCCCTGAGGGCTGCAC GGGGCACTTACAGGGTGAC 180 60
5b GGCTTCAAGGTGGACATCTG CTGTGGCCAGAGAGGGTCT 161 60
6 TCAACCACCTTGACTGACCA ACCCCCAACCCTACATTTCT 249 60
7 CCTTAGGAGCGTCCAGGTATC CTCAACCAGCTGCCCACAT 244 60
8a CTGGGTCGGAAAACTGGAC GTGCAGGTCCTCCAAGTACG 182 60
8b GAGCCCAGACACCAAGGAC GACATCCTGGCCGAGTCA 188 60
9 TCAGCTCAGGCCACACTTGC AGCCTCACTGCTGCTTGC 232 60
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webcite) was used to describe sequence variations with +1
corresponding to the A of the ATG translation initiation
codon of GeneBank NM_000455 for STK11.
Results
Small STK11 gene mutations were detected in 22 fam-
ilies (54%) seven of which were novel, so far undescribed
changes (Table 2). Mutations were detected in all gene
coding exons with the exception of exons 3 and 9.Table 2 List of small mutations detected in the course of the
Exon Nucleotide change Codon
1 c.157_158dupG [16] 53
c.160_161insC* 54
c.178delT* 60
c.180C > G [17] 60
2 c.291-1G > C [18]
4 c.474delT* 158
c.481A > T* 161
c.488G > A [19] 163
c.493G > T [19] 165
580G > A [20] 194
5 c.733C > T* 245
6 c.735-10C > A [19]
c.790_793delTTTG [21] 264





*novel mutation.Distinct disproportions in the distribution of mutations
were apparent. A majority of the detected changes oc-
curred in exons 1, 4 and 7. The examination of exon 1
revealed the presence of 4 kinds of mutations of which
two were novel ones, so far undescribed in literature
(c.160_161insC, c.178delT). The third change was the
earlier observed nonsense mutation c.180C > G the con-
sequence of which was the appearance of the premature
stop codon in position 60 (p.Tyr60X). The fourth muta-
tion in this exon was c.157_158dupG which creates astudy

















Splice site mutation 1
p.Val337GlyfsX22 1
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Asp53Glyfsx110). Five kinds of mutations (c.474delT,
c.481A > T, c.488G > A, c.493G > T, c.580G > A) were
detected in exon 4 in seven of the examined families
(Figure 1). The most frequent mutation (detected in 3
families) was the G > A substitution in position 580
resulting in a p.Asp194Asn amino acid substitution. The
performed analysis of exon 7 revealed the presence of 3
kinds of mutations in 5 of the examined families.Figure 1 The example HRM analysis of exon 4 of the STK11 gene; gre
type; A. Melt profile B. HRM analysis.Changes of c.910delC and c.876C >G were observed
twice, whereas in one case, an undescribed 16-nucleotide
deletion –c.867_882delGCTTGAGTACGAACCG – was
detected (Figure 2). Single sequence changes were
detected in exons 5 (c.733C > T), 6 (c.790_793delTTTG)
and 8 (c.1010_1011delTG).
Apart from changes in the coding sequence, the
performed investigations also made it possible to detect
changes in the intron sequence embraced by the primersen curve - c.493G > T, red curve - c.488G > A, blue curve - wild
Figure 2 The example HRM analysis of exon 7 of the STK11 gene (1nt deletion and SNP class III); green curve - c.910delC, red
curve - c.876C > G, blue curve - wild type; A. Melt profile B. HRM analysis.
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was observed within the splicing site. In addition, muta-
tions were also detected in intron 7 (c.921-4_921-
2delGCA). The functional consequences of the
c.735 10C > A change in intron 5 are unclear. Bioinfor-
matic analysis performed with the SpliceView (http://
zeus2.itb.cnr.it) software and the algorithm available
from the University of California Berkeley website
(http://www.fruitfly.org/seq_tools/splice.html) showed
the potential creation of a new acceptor splicing site
(scores 90 and 0.99 respectively). However, in order to
confirm this hypothesis further investigations on the pa-
tient’s mRNA should be carried out.The sequencing of the entire STK11 coding sequence
for patients in whom no evident pathogenic mutations
were detected in the course of the HRM analysis failed
to detect additional changes.
Discussion
High resolution melting provides a rapid and effective
screening tool for unknown mutations. This method al-
lows to detect not only small mutations such as inser-
tions, duplications or deletions of one or several
nucleotides but also substitutions (including class 3
SNPs, e.g. c.876C > G and class 4 e.g. c.481A > T difficult
to detect). In the same group of patients the mutations:
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c.735-10C > A were not detected during previous studies
using Single Strand Conformation Polymorphism (SSCP)
and Heteroduplex analysis (HA) (unpublished results).
Thereby, the use of HRM as a screening method allowed
us to increase the detection efficiency in our group of
patients mainly by improving the detectability of muta-
tions from classes 3 and 4.
In the studies of other populations the most common
method used for the detection of small mutations in PJS
patients is direct sequencing [8,17,22,24,25]. Only in few
studies Denaturing High Performance Liquid Chroma-
tography (DHPLC) [8] or older screening techniques
such as DGGE, SSCP and HA were also used [26,27].
Depending on the studied group and the methodology
used, the detection efficiency of small mutations in the
above-mentioned groups is in the range from 42.42% to
70%. Therefore, the level of detection in our study with
the use of HRM (54%) does not differ from the level of
small mutations detection obtained using direct sequen-
cing or other screening methods. It should be taken into
account that in contrast to direct sequencing the use of
screening methods allows to considerably lower the
costs of analysis by reducing the number of samples
subjected to sequencing. On the other hand, the advan-
tage of HRM over other screening methods is its simpli-
city of implementation. Moreover, time required to
perform the analysis, in comparison with other screening
methods, also speaks in favor of HRM. The entire ana-
lysis, including the preparation of the reaction mixture,
amplification and melting of the products takes a little
more than 2 hours. The Rotor-Gene Q, utilising the
rotor for 0.1 ml tubes, makes it possible to analyze dur-
ing this time up to 72 amplicons simultaneously. In
addition, none of the reagents present in the mixture in-
terferes with the sequencing reaction and, therefore, it is
possible to conduct sequencing directly from products
previously analyzed by HRM.
Among other advantages of the HRM analysis is its
single-step way of reaction preparation. Both the amplifi-
cation itself as well as the subsequent fragment melting
takes place in a closed system of an identical compos-
ition of the reaction mixture. No reagents need to be
added in the course of the analysis which reduces the
risk of sample contamination and falsification of the
obtained results. In addition, the presence of the fluores-
cent dye throughout the duration of the reaction makes
it possible to monitor not only the melting process but
also the PCR itself. This opens up possibilities for de-
signing in the future of a test detecting small mutations
(HRM) combined with a simultaneous quantitative ana-
lysis on the basis of amplification curves (qPCR). The
approach combining the qPCR with the HRM analysis
has been already proposed by Rouleau et al. for testingthe MLH1 gene [28]. However, the qPCR analysis re-
quires the use of a significant number of samples with
known parameters to create a standard curve for each
amplicon. In addition, each sample should be analyzed
in replicates to properly quantify target amplicons.
These two aspects significantly increase the costs of the
analysis. The qPCR-HRM approach seems to be suitable
and beneficial only for a large series of samples and it
should be taken into account that PJS is a rare disease
and usually only few samples are analyzed at the same
time.
The key issue in the HRM analysis is the appropriate
selection of primers for the amplification of the exam-
ined fragments so that the obtained melting profiles
make it possible to observe the occurring sequence
changes. In case of the STK11 gene, high GC content
reaching 63% for the entire gene sequence constitutes an
additional difficulty in primer designing. Primers se-
lected in the course of our study make it possible to ob-
tain uniform PCR products meeting the requirements of
the HRM analysis. In addition, the annealing temperature
is identical for all primer pairs thus it is possible to
perform screening of several exons, or even of the entire
sequence coding the STK11 gene in the course of one ana-
lysis. This is particularly important in case of investiga-
tions of such rare diseases as PJS where patient groups are
small and only several samples are analyzed in the course
of one examination and examination of each fragment
separately would both be time-consuming and unprofit-
able (low cost-effectiveness).Conclusions
In our experiments we developed a method for a rapid
detection of small mutations in the STK11 gene in pa-
tients suffering from PJS. All mutations identified in our
group of patients were detected with the assistance of
the evaluated method. No additional small mutations
were found in the remaining patients subjected to the
sequencing of the entire sequence coding the gene. The
employed HRM method exhibited 100% sensitivity in
our group of patients.
Competing interests
The authors declare that they have no competing interests.Authors’ contributions
PB-developed a method for a rapid detection of small mutations in the
STK11 gene, prepared the DNA samples, performed molecular analysis and
drafted the manuscript. AB-prepared the DNA samples and participated in
molecular analysis, TB, BN, DN, MT, JL, JL, JW, EC, MS, AK, WC and PK were
responsible for PJS patients diagnosis and sample collections. PK participated
in sample collection and drafted the manuscript. WC participated in
coordination, and helped to draft the manuscript. AP developed the
method, performed molecular analysis, drafted the manuscript and
supervised all the work, conceived of the study. All authors read and
approved the final manuscript.
Borun et al. BMC Medical Genetics 2013, 14:58 Page 7 of 7
http://www.biomedcentral.com/1471-2350/14/58Acknowledgements
The study was financed by the Ministry of Education and Science, Poland,
grant number N402 481537.
Author details
1Institute of Human Genetics, Polish Academy of Sciences, Strzeszyńska 32,
60-479, Poznan, Poland. 2Department of General, Gastroenterological and
Endocrinological Surgery, Poznan University of Medical Sciences, Poznan,
Poland. 3Department of Dermatology, Venereology and Allergology, Medical
University of Gdansk, Gdansk, Poland. 4Maria Sklodowska-Curie Memorial
Cancer Centre and Institute of Oncology, Warsaw, Poland. 5Department of
Gastroenterology, Hepatology and Immunology, Children's Memorial Health
Institute, Warsaw, Poland. 6Department of Biology and Genetics, Medical
University of Gdansk, Gdansk, Poland. 7International Hereditary Cancer
Center, Department of Genetics and Pathology, Pomeranian Medical
University, Szczecin, Poland. 8Fourth Clinical Hospital, University of Medical
Sciences, Poznan, Poland. 9First Chair of Pediatrics, Department of Pediatric
Gastroenterology and Metabolic Diseases, University of Medical Sciences,
Poznan, Poland. 10Department of General and Colorectal Surgery, Poznan
University of Medical Sciences, Poznan, Poland. 11Department of
Gastroenterology, the Polish Mother's Memorial Hospital, Research Institute
in Lodz, Lodz, Poland. 12Holy Cross Oncology Center, Kielce, Poland.
Received: 23 November 2012 Accepted: 23 May 2013
Published: 30 May 2013References
1. Schreibman IR, Baker M, Amos C, McGarrity TJ: The hamartomatous
polyposis syndromes: a clinical and molecular review. Am J Gastroenterol
2005, 100(2):476–490.
2. Giardiello FM, Trimbath JD: Peutz-Jeghers syndrome and management
recommendations. Clin Gastroenterol Hepatol 2006, 4(4):408–415.
3. Beggs AD, Latchford AR, Vasen HF, Moslein G, Alonso A, Aretz S, Bertario L,
Blanco I, Bulow S, Burn J, et al: Peutz-Jeghers syndrome: a systematic
review and recommendations for management. Gut 2010, 59(7):975–986.
4. Tomlinson IP, Houlston RS: Peutz-Jeghers syndrome. J Med Genet 1997,
34(12):1007–1011.
5. Resta N, Pierannunzio D, Lenato GM, Stella A, Capocaccia R, Bagnulo R,
Lastella P, Susca FC, Bozzao C, Loconte DC, et al: Cancer risk associated
with STK11/LKB1 germline mutations in Peutz-Jeghers syndrome
patients: Results of an Italian multicenter study. Dig Liver Dis 2013,
S1590-8658(12):00496–3.
6. Alessi DR, Sakamoto K, Bayascas JR: LKB1-dependent signaling pathways.
Annu Rev Biochem 2006, 75:137–163.
7. Karuman P, Gozani O, Odze RD, Zhou XC, Zhu H, Shaw R, Brien TP, Bozzuto
CD, Ooi D, Cantley LC, et al: The Peutz-Jegher gene product LKB1 is a
mediator of p53-dependent cell death. Mol Cell 2001, 7(6):1307–1319.
8. Aretz S, Stienen D, Uhlhaas S, Loff S, Back W, Pagenstecher C, McLeod DR,
Graham GE, Mangold E, Santer R, et al: High proportion of large genomic
STK11 deletions in Peutz-Jeghers syndrome. Hum Mutat 2005,
26(6):513–519.
9. Chow E, Meldrum CJ, Crooks R, Macrae F, Spigelman AD, Scott RJ: An
updated mutation spectrum in an Australian series of PJS patients
provides further evidence for only one gene locus. Clin Genet 2006,
70(5):409–414.
10. Hearle NC, Rudd MF, Lim W, Murday V, Lim AG, Phillips RK, Lee PW,
O'Donohue J, Morrison PJ, Norman A, et al: Exonic STK11 deletions are not
a rare cause of Peutz-Jeghers syndrome. J Med Genet 2006, 43(4):e15.
11. Volikos E, Robinson J, Aittomaki K, Mecklin JP, Jarvinen H, Westerman AM,
de Rooji FW, Vogel T, Moeslein G, Launonen V, et al: LKB1 exonic and
whole gene deletions are a common cause of Peutz-Jeghers syndrome.
J Med Genet 2006, 43(5):e18.
12. De Rosa M, Galatola M, Quaglietta L, Miele E, De Palma G, Rossi GB, Staiano
A, Izzo P: Alu-mediated genomic deletion of the serine/threonine protein
kinase 11 (STK11) gene in Peutz-Jeghers syndrome. Gastroenterology
2010, 138(7):2558–2560.
13. Reed GH, Wittwer CT: Sensitivity and specificity of single-nucleotide
polymorphism scanning by high-resolution melting analysis. Clin Chem
2004, 50(10):1748–1754.14. Reed GH, Kent JO, Wittwer CT: High-resolution DNA melting analysis for
simple and efficient molecular diagnostics. Pharmacogenomics 2007,
8(6):597–608.
15. Erali M, Wittwer CT: High resolution melting analysis for gene scanning.
Methods 2010, 50(4):250–261.
16. Trojan J, Brieger A, Raedle J, Roth WK, Zeuzem S: Peutz-Jeghers syndrome:
molecular analysis of a three-generation kindred with a novel defect in
the serine threonine kinase gene STK11. Am J Gastroenterol 1999,
94(1):257–261.
17. Olschwang S, Boisson C, Thomas G: Peutz-Jeghers families unlinked to
STK11/LKB1 gene mutations are highly predisposed to primitive biliary
adenocarcinoma. J Med Genet 2001, 38(6):356–360.
18. Nakagawa H, Koyama K, Miyoshi Y, Ando H, Baba S, Watatani M, Yasutomi
M, Matsuura N, Monden M, Nakamura Y: Nine novel germline mutations of
STK11 in ten families with Peutz-Jeghers syndrome. Hum Genet 1998,
103(2):168–172.
19. Lim W, Olschwang S, Keller JJ, Westerman AM, Menko FH, Boardman LA,
Scott RJ, Trimbath J, Giardiello FM, Gruber SB, et al: Relative frequency and
morphology of cancers in STK11 mutation carriers. Gastroenterology 2004,
126(7):1788–1794.
20. Schumacher V, Vogel T, Leube B, Driemel C, Goecke T, Moslein G, Royer-
Pokora B: STK11 genotyping and cancer risk in Peutz-Jeghers syndrome.
J Med Genet 2005, 42(5):428–435.
21. Thakur N, Reddy DN, Rao GV, Mohankrishna P, Singh L, Chandak GR: A
novel mutation in STK11 gene is associated with Peutz-Jeghers
Syndrome in Indian patients. BMC Med Genet 2006, 7:73.
22. Papp J, Kovacs ME, Solyom S, Kasler M, Borresen-Dale AL, Olah E: High
prevalence of germline STK11 mutations in Hungarian Peutz-Jeghers
Syndrome patients. BMC Med Genet 2010, 11:169.
23. Salloch H, Reinacher-Schick A, Schulmann K, Pox C, Willert J, Tannapfel A,
Heringlake S, Goecke TO, Aretz S, Stemmler S, et al: Truncating mutations
in Peutz-Jeghers syndrome are associated with more polyps, surgical
interventions and cancers. Int J Colorectal Dis 2010, 25(1):97–107.
24. Weng MT, Ni YH, Su YN, Wong JM, Wei SC: Clinical and genetic analysis of
Peutz-Jeghers syndrome patients in Taiwan. J Formos Med Assoc 2010,
109(5):354–361.
25. Vasovcak P, Puchmajerova A, Roubalik J, Krepelova A: Mutations in STK11
gene in Czech Peutz-Jeghers patients. BMC Med Genet 2009, 10:69.
26. Westerman AM, Entius MM, Boor PP, Koole R, de Baar E, Offerhaus GJ,
Lubinski J, Lindhout D, Halley DJ, de Rooij FW, et al: Novel mutations in
the LKB1/STK11 gene in Dutch Peutz-Jeghers families. Hum Mutat 1999,
13(6):476–481.
27. Hearle N, Schumacher V, Menko FH, Olschwang S, Boardman LA, Gille JJ,
Keller JJ, Westerman AM, Scott RJ, Lim W, et al: STK11 status and
intussusception risk in Peutz-Jeghers syndrome. J Med Genet 2006,
43(8):e41.
28. Rouleau E, Lefol C, Bourdon V, Coulet F, Noguchi T, Soubrier F, Bieche I,
Olschwang S, Sobol H, Lidereau R: Quantitative PCR high-resolution
melting (qPCR-HRM) curve analysis, a new approach to simultaneously
screen point mutations and large rearrangements: application to MLH1
germline mutations in Lynch syndrome. Hum Mutat 2009, 30(6):867–875.
doi:10.1186/1471-2350-14-58
Cite this article as: Borun et al.: High Resolution Melting analysis as a
rapid and efficient method of screening for small mutations in the
STK11 gene in patients with Peutz-Jeghers syndrome. BMC Medical
Genetics 2013 14:58.
